Results
74,087 records
Include
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS |  TBPHTheravance Biopharma, Inc.Open-market sale · 10b5-1 plan | SELL | $113K 6,657 sh |
Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramEvery ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | TBPHTheravance Biopharma, Inc. Open-market sale · 10b5-1 plan | SELL | $113K 6,657 sh |
| Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | TBPHTheravance Biopharma, Inc. Open-market sale · 10b5-1 plan | SELL | $57K 3,328 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Choudary Kiran KumarChief Financial Officer |  RBRKRubrik, Inc.Tax withholding · 10b5-1 plan | F | $1.40M 14.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | TBPHTheravance Biopharma, Inc. Open-market sale · 10b5-1 plan | SELL | $57K 3,329 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary |  VGVenture Global, Inc.Option exercise · 10b5-1 plan | M | — 395.0K sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER |  QSQuantumScape CorpDerivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Cline Christopher R.CHIEF FINANCIAL OFFICER |  TVTXTravere Therapeutics, Inc.Option exercise · 10b5-1 plan | M | — 20.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing |  MASS908 Devices Inc.Option exercise · 10b5-1 plan | M | — 21.4K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER | QSQuantumScape Corp Derivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | McClymont DonaldDirector, Chief Executive Officer |  INDIindie Semiconductor, Inc.Option exercise · 10b5-1 plan | M | — 50.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | — 5,257 sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | — 239.3K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | — 155.7K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Tariq MusaDirector |  GHGuardant Health, Inc.Option exercise · 10b5-1 plan | M | — 249 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,500 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Hanson Scott McLeanDirector, Chief Technology Officer |  AMBQAmbiq Micro, Inc.Option exercise · 10b5-1 plan | M | $57K 7,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | $131K 155.7K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER | QSQuantumScape Corp Derivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | How AntoinetteChief Accounting Officer |  NXDRNextdoor Holdings, Inc.Derivative conversion · 10b5-1 plan | C | — 154.9K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kirchhoff Benjamin LouisCHIEF ACCOUNTING OFFICER |  IOTSamsara Inc.Tax withholding · 10b5-1 plan | F | $65K 1,514 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Fordyce MarshallDirector, PRESIDENT AND CEO |  VERAVera Therapeutics, Inc.Option exercise · 10b5-1 plan | M | — 18.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $33K 1,625 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $28K 1,250 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | $960 1,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | $332K 395.0K sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Choudary Kiran KumarChief Financial Officer | RBRKRubrik, Inc. Derivative conversion · 10b5-1 plan | C | — 4,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Choudary Kiran KumarChief Financial Officer | RBRKRubrik, Inc. Option exercise · 10b5-1 plan | M | — 4,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Choudary Kiran KumarChief Financial Officer | RBRKRubrik, Inc. Derivative conversion · 10b5-1 plan | C | — 4,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Hanson Scott McLeanDirector, Chief Technology Officer | AMBQAmbiq Micro, Inc. Option exercise · 10b5-1 plan | M | — 7,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Fordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $54K 18.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | — 1,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | $5,047 5,257 sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Tariq MusaDirector | GHGuardant Health, Inc. Option exercise · 10b5-1 plan | M | — 249 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | McClymont DonaldDirector, Chief Executive Officer | INDIindie Semiconductor, Inc. Option exercise · 10b5-1 plan | M | — 50.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER | QSQuantumScape Corp Derivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | How AntoinetteChief Accounting Officer | NXDRNextdoor Holdings, Inc. Option exercise · 10b5-1 plan | M | — 154.9K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | How AntoinetteChief Accounting Officer | NXDRNextdoor Holdings, Inc. Option exercise · 10b5-1 plan | M | — 154.9K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | How AntoinetteChief Accounting Officer | NXDRNextdoor Holdings, Inc. Derivative conversion · 10b5-1 plan | C | — 154.9K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,625 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | McClymont DonaldDirector, Chief Executive Officer | INDIindie Semiconductor, Inc. Option exercise · 10b5-1 plan | M | — 50.0K sh | Sep 17, 2026 traded Sep 15, 2026 |